Hillstream BioPharma (HILS) Competitors $2.06 -0.09 (-4.19%) (As of 12/27/2024) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends HILS vs. SGMT, GLSI, MCRB, NBTX, BMEA, RENB, TELO, MNPR, PEPG, and XBITShould you be buying Hillstream BioPharma stock or one of its competitors? The main competitors of Hillstream BioPharma include Sagimet Biosciences (SGMT), Greenwich LifeSciences (GLSI), Seres Therapeutics (MCRB), Nanobiotix (NBTX), Biomea Fusion (BMEA), Renovaro (RENB), Telomir Pharmaceuticals (TELO), Monopar Therapeutics (MNPR), PepGen (PEPG), and XBiotech (XBIT). These companies are all part of the "pharmaceutical preparations" industry. Hillstream BioPharma vs. Sagimet Biosciences Greenwich LifeSciences Seres Therapeutics Nanobiotix Biomea Fusion Renovaro Telomir Pharmaceuticals Monopar Therapeutics PepGen XBiotech Hillstream BioPharma (NASDAQ:HILS) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Does the media favor HILS or SGMT? In the previous week, Sagimet Biosciences had 2 more articles in the media than Hillstream BioPharma. MarketBeat recorded 2 mentions for Sagimet Biosciences and 0 mentions for Hillstream BioPharma. Sagimet Biosciences' average media sentiment score of 1.34 beat Hillstream BioPharma's score of 0.00 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Hillstream BioPharma Neutral Sagimet Biosciences Positive Which has better valuation & earnings, HILS or SGMT? Hillstream BioPharma has higher earnings, but lower revenue than Sagimet Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHillstream BioPharmaN/AN/A-$8.47M-$0.72-2.86Sagimet Biosciences$2M68.87-$27.88MN/AN/A Do institutionals & insiders believe in HILS or SGMT? 13.4% of Hillstream BioPharma shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 30.2% of Hillstream BioPharma shares are held by insiders. Comparatively, 17.6% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor HILS or SGMT? Sagimet Biosciences received 25 more outperform votes than Hillstream BioPharma when rated by MarketBeat users. Likewise, 96.30% of users gave Sagimet Biosciences an outperform vote while only 50.00% of users gave Hillstream BioPharma an outperform vote. CompanyUnderperformOutperformHillstream BioPharmaOutperform Votes150.00% Underperform Votes150.00% Sagimet BiosciencesOutperform Votes2696.30% Underperform Votes13.70% Do analysts rate HILS or SGMT? Sagimet Biosciences has a consensus target price of $23.00, indicating a potential upside of 412.25%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Sagimet Biosciences is more favorable than Hillstream BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sagimet Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has more risk & volatility, HILS or SGMT? Hillstream BioPharma has a beta of 3.08, meaning that its share price is 208% more volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 2.3, meaning that its share price is 130% more volatile than the S&P 500. Is HILS or SGMT more profitable? Sagimet Biosciences' return on equity of -23.63% beat Hillstream BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Hillstream BioPharmaN/A -188.44% -149.61% Sagimet Biosciences N/A -23.63%-22.91% SummarySagimet Biosciences beats Hillstream BioPharma on 11 of the 14 factors compared between the two stocks. Ad Paradigm Press Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!Click here now for the urgent details. Get Hillstream BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HILS vs. The Competition Export to ExcelMetricHillstream BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.26M$6.61B$5.18B$8.94BDividend YieldN/A2.96%4.99%4.13%P/E Ratio-2.8610.7187.8117.11Price / SalesN/A177.871,169.48120.66Price / CashN/A57.1443.2637.89Price / Book4.295.195.125.07Net Income-$8.47M$150.98M$120.45M$226.29M7 Day Performance-3.29%1.18%1.10%1.09%1 Month Performance-0.96%-4.39%17.00%2.26%1 Year Performance304.72%4.17%29.14%18.72% Hillstream BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HILSHillstream BioPharmaN/A$2.06-4.2%N/A+793.7%$36.26MN/A-2.861SGMTSagimet Biosciences2.6125 of 5 stars$4.72-4.5%$23.00+387.3%-17.0%$144.79M$2M0.008News CoveragePositive NewsGLSIGreenwich LifeSciences2.241 of 5 stars$10.91-5.1%$38.00+248.3%+6.7%$143.41MN/A-13.643Short Interest ↑News CoverageMCRBSeres Therapeutics3.2963 of 5 stars$0.83-6.4%$5.08+512.4%-40.6%$141.71M$126.33M-3.61233News CoverageGap UpNBTXNanobiotix1.8504 of 5 stars$2.99-0.3%$12.00+301.3%-60.6%$140.93M$36.22M0.00100Negative NewsGap UpBMEABiomea Fusion3.8989 of 5 stars$3.88-3.0%$39.36+914.5%-73.3%$140.61MN/A-0.9750Short Interest ↑Positive NewsRENBRenovaro0.6032 of 5 stars$0.87-5.1%N/A-73.6%$138.18MN/A-0.9112Gap UpTELOTelomir PharmaceuticalsN/A$4.64-4.7%N/AN/A$137.39MN/A0.001Gap DownMNPRMonopar Therapeutics2.4199 of 5 stars$23.85-2.8%$27.33+14.6%+1,193.4%$125.88MN/A-12.1110PEPGPepGen2.2536 of 5 stars$3.83-2.3%$13.67+256.8%-44.3%$124.84MN/A-1.2972XBITXBiotech0.5301 of 5 stars$4.09+7.6%N/A-1.3%$124.68M$4.01M-3.79100News Coverage Related Companies and Tools Related Companies SGMT Competitors GLSI Competitors MCRB Competitors NBTX Competitors BMEA Competitors RENB Competitors TELO Competitors MNPR Competitors PEPG Competitors XBIT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HILS) was last updated on 1/2/2025 by MarketBeat.com Staff From Our Partners3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementUnder-the-Radar Crypto Could Soar by Jan. 20th Investors in the know could bank HUGE profits! Crypto 101 Media | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Next Big Thing in AI: Musk’s Secret SupplierWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hillstream BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hillstream BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
